

List of excluded studies for clinical effectiveness and adverse events reviews

Publications	Reason(s) for exclusion
1. Pradalier A, Rancurel G, Dordain G, Verdure L, Rascol A, Dry J. Acute Migraine Attack Therapy: Comparison of Naproxen Sodium and an Ergotamine Tartrate Compound. <i>Cephalalgia</i> . 1985;5(2):107-113. doi: 10.1046/j.1468-2982.1985.0502107.x	Acute Migraine
2. Abbasi V, Atalu A, Seddighnia P. Comparison of Levetiracetam and sodium Valproate in the prevention of migraine: a randomized clinical trial study. <i>International Journal of Basic & Clinical Pharmacology</i> . 2018 Aug;7(8):1460.	Small sample size of episodic migraine
3. Krakowski AJ, Engisch R. A new agent for chemotherapy of migraine headaches: a controlled study. <i>Psychosomatics: Journal of Consultation and Liaison Psychiatry</i> . 1973 Sep.	Small sample size of episodic migraine
4. Adam EI, Gore SM, Price WH. Double blind trial of clonidine in the treatment of migraine in a general practice. <i>The Journal of the Royal College of General Practitioners</i> . 1978 Oct 1;28(195):587-90.	Small sample size of episodic migraine
5. Soares AD, Louçana PM, Nasi EP, Sousa KM, Sá OM, Silva-Néto RP. A double-blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA ω -3) for the prevention of migraine in chronic migraine patients using amitriptyline. <i>Nutritional neuroscience</i> . 2018 Mar 16;21(3):219-23.	Small chronic trial
6. Afshari D, Rafizadeh S, Rezaei M. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. <i>International journal of Neuroscience</i> . 2012 Jan 1;122(2):60-8.	Small sample size of episodic migraine
7. Allais G, De Lorenzo C, Quirico PE, Airola G, Tolardo G, Mana O, Benedetto C. Acupuncture in the prophylactic treatment of migraine without aura: a comparison with flunarizine. <i>Headache: The Journal of Head and Face Pain</i> . 2002 Oct;42(9):855-61.	Small sample size of episodic migraine
8. Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, Connor KM, Michelson D. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. <i>Cephalalgia</i> . 2015 Apr;35(5):379-88.	Not available in the market
9. Andersson PG, Dahl S, Hansen JH, Hansen PE, Hedman C, Nygaard Kristensen T, de Fine Olivarius B. Prophylactic treatment of classical and non-classical migraine with metoprolol—a comparison with placebo. <i>Cephalalgia</i> . 1983 Dec;3(4):207-12.	Small sample size of episodic migraine
10. Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. <i>BMC neurology</i> . 2018 Dec;18(1):1-2.	A safety study, different Galcanezumab doses.
11. Ansell E, Fazzone T, Festenstein R, Johnson ES, Thavapalan M, Wilkinson M, Wozniak I. Nimodipine in migraine prophylaxis. <i>Cephalalgia</i> . 1988 Dec;8(4):269-72.	Small sample size of episodic migraine
12. Bostani A, Rajabi A, Moradian N, Razazian N, Rezaei M. The effects of cinnarizine versus sodium valproate in migraine prophylaxis. <i>International Journal of Neuroscience</i> . 2013 Jul 1;123(7):487-93.	Not clear if chronic, small sample size
13. Ashina M, Doležil D, Bonner JH, Zhou L, Klatt J, Picard H, Mikol DD. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. <i>Cephalalgia</i> . 2021 Jan;41(1):33-44.	Only 190 chronic participants reported in supplementary. This product is also not marketed.
14. Assarzagdegan F, Tabesh H, Hosseini-Zijoud SM, Beale AD, Shoghli A, Yazdi MG, Mansouri B, Hesami O, Moghadam NB, Kasmaei HD. Comparing zonisamide with sodium valproate in the management of	Small sample size of episodic migraine

migraine headaches: double-blind randomized clinical trial of efficacy and safety. Iranian Red Crescent Medical Journal. 2016 Sep;18(9).	
15. Barrientos N, Chana P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. The Journal of headache and pain. 2003 Dec;4(3):146-51.	Small sample size of episodic migraine
16. Bavrasad R, Nejad SE, Yarahmadi AR, Sajedi SI, Rahim F. Assessment of the middle dose of topiramate in comparison with sodium valproate for migraine prophylaxis: a randomized-double-blind study. International Journal of Pharmacology. 2010 Sep 1;6(5):670-5.	Small sample size of episodic migraine
17. Beran RG, Spira PJ. Levetiracetam in chronic daily headache: A double-blind, randomised placebo-controlled study: (The Australian KEPBRA Headache Trial [AUS-KHT]). Cephalalgia. 2011 Apr;31(5):530-6.	Small sample size of chronic headache day
18. Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, Loupe PS, Ma Y, Goadsby PJ. TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology. 2016 Jul 5;87(1):41-8.	Small size of chronic migraine
19. Blumenfeld AM, Stevanovic DM, Ortega M, Cohen JM, Seminerio MJ, Yang R, Jiang B, Tepper SJ. No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study. Headache: The Journal of Head and Face Pain. 2020 Nov;60(10):2431-43.	Wearing-Off effect study
20. Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache: The Journal of Head and Face Pain. 2008 Feb;48(2):210-20.	Small size of mixed population
21. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, Neto W, Schwabe S, Jacobs D, MIGR-002 Study Group, MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. Jama. 2004 Feb 25;291(8):965-73.	The mixed population of adults and adolescence
22. Standnes B. The prophylactic effect of timolol versus propranolol and placebo in common migraine: beta-blockers in migraine. Cephalalgia. 1982 Sep;2(3):165-70.	Too small size
23. Broessner G, Reuter U, Bonner JH, Dodick DW, Hallström Y, Picard H, Zhang F, Lenz RA, Klatt J, Mikol DD. The spectrum of response to erenumab in patients with episodic migraine and subgroup analysis of patients achieving $\geq 50\%$, $\geq 75\%$, and 100% response. Headache: The Journal of Head and Face Pain. 2020 Oct;60(9):2026-40.	No report of adverse events
24. Bruno MA, Krymchantowski AV. Amitriptyline and intraoral devices for migraine prevention: a randomized comparative trial. Arquivos de Neuro-Psiquiatria. 2018;76:213-8.	Small sample size of episodic migraine
25. R. K. Cady, C. P. Schreiber, J. A. H. Porter, A. M. Blumenfeld, and K. U. Farmer, "A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine," <i>Headache: The Journal of Head and Face Pain</i> , vol. 51, no. 1, pp. 21–32, 2011.	Small sample size
26. Cady RK, Voirin J, Farmer K, Browning R, Beach ME, Tarrasch J. Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topiramate: research and clinical implications. Headache: The Journal of Head and Face Pain. 2012 May;52(5):749-64.	Small sample size of episodic migraine
27. Cao K, Han F, Lin A, Yang W, Zhao J, Zhang H, Ding Y, Xie W, Xu Y, Yu T, Wang X. Zhengtian Capsule versus flunarizine in patients with migraine: a multi-center, double-blind, double-dummy, randomized controlled, non-inferior clinical trial. BMC complementary and alternative medicine. 2016 Dec;16(1):1-0.	Herbal remedy not prescribed on NHS

28. Chankrachang S, Arayawichanon A, Pongvarin N, Nidhinandana S, Boonkongchuen P, Towanabut S, Sithinamsuwan P, Kongsangdao S. Prophylactic botulinum type A toxin complex (Dysport®) for migraine without aura. <i>Headache: The Journal of Head and Face Pain</i> . 2011 Jan;51(1):52-63.	Small sample size
29. Charles JA, Jotkowitz S, Byrd LH. Prevention of migraine with olmesartan in patients with hypertension/prehypertension. <i>Headache: The Journal of Head and Face Pain</i> . 2006 Mar;46(3):503-7.	Small sample size of different doses of the same drug, no placebo/control
30. Christensen CE, Younis S, Deen M, Khan S, Ghanizada H, Ashina M. Migraine induction with calcitonin gene-related peptide in patients from erenumab trials. <i>The Journal of Headache and Pain</i> . 2018 Dec;19(1):1-9.	Question not relevant, not a trial of migraine prevention
31. Couch JR, Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. <i>Headache: The Journal of Head and Face Pain</i> . 2011 Jan;51(1):33-51.	Small sample size
32. Yang CP, Chang MH, Liu PE, Li TC, Hsieh CL, Hwang KL, Chang HH. Acupuncture versus topiramate in chronic migraine prophylaxis: a randomized clinical trial. <i>Cephalalgia</i> . 2011 Nov;31(15):1510-21.	Small sample size
33. d'Amato CC, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A. Fluoxetine for migraine prophylaxis: a double-blind trial. <i>Headache: The Journal of Head and Face Pain</i> . 1999 Nov;39(10):716-9.	Small sample size
34. Buse DC, Lipton RB, Hallström Y, Reuter U, Tepper SJ, Zhang F, Sapiro S, Picard H, Mikol DD, Lenz RA. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. <i>Cephalalgia</i> . 2018 Sep;38(10):1622-31.	No report of adverse events
35. Diener HC, Krupp P, Schmitt T, Steitz G, Milde K, Freytag S, Study Group. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study. <i>Cephalalgia</i> . 2001 Feb;21(1):66-70.	No report of adverse events
36. Diener HC, Fischer M, Laccarino C, Wessely P, Isler H, Stienge H, Fischer M, Wedekind W, Taneri Z. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. <i>Cephalalgia</i> . 1996 Oct;16(6):441-7.	Small sample size
37. Diener HC, Hartung E, Chrubasik JO, Evers S, Schoenen J, Eikermann A, Latta G, Hauke W, Study Group. A comparative study of oral acetylsalicylic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study. <i>Cephalalgia</i> . 2001 Mar;21(2):120-8.	No report of adverse events
38. Diener HC, Bussone G, Oene JV, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. <i>Cephalalgia</i> . 2007 Jul;27(7):814-23.	Small sample size
39. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, Botox CDH Study Group. Botulinum toxin type A for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study. <i>Headache: The Journal of Head and Face Pain</i> . 2005 Apr;45(4):315-24.	CDH of which CM is a subset, but as not specific to CM
40. Domingues RB, Silva AL, Domingues SA, Aquino CC, Kuster GW. A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine. <i>Arquivos de neuro-psiquiatria</i> . 2009;67:973-7.	Small sample size
41. Magalhães E, Menezes C, Cardeal M, Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. <i>Clinical neurology and neurosurgery</i> . 2010 Jul 1;112(6):463-6.	Small sample size

42. Magalhães E, Menezes C, Cardeal M, Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. <i>Clinical neurology and neurosurgery</i> . 2010 Jul 1;112(6):463-6.	Small sample size
43. Faraji F, Zarinfar N, Zanjani AT, Morteza A. The effect of Helicobacter pylori eradication on migraine: a randomized, double blind, controlled trial. <i>Pain physician</i> . 2012;15(6):495.	This is eradication of HP not use of a prophylactic treatment
44. Ford JH, Ayer DW, Zhang Q, Carter JN, Leroux E, Skljarevski V, Aurora SK, Tockhorn-Heidenreich A, Lipton RB. Two randomized migraine studies of galcanezumab: effects on patient functioning and disability. <i>Neurology</i> . 2019 Jul 30;93(5):e508-17.	No report of adverse events
45. Freitag FG, Diamond S, Diamond M, Urban G. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. <i>Headache: The Journal of Head and Face Pain</i> . 2008 Feb;48(2):201-9.	Small sample size
46. Lauretti GR, Rosa CP, Kitayama A, Lopes BC. Comparison of botox® or prosigne® and facial nerve blockade as adjuvant in chronic migraine. <i>Journal of Biomedical Science and Engineering</i> . 2014 Jun 26;2014.	Small sample size
47. Ganji R, Majdinasab N, Hesam S, Rostami N, Sayyah M, Sahebhasagh A. Does atorvastatin have augmentative effects with sodium valproate in prevention of migraine with aura attacks? A triple-blind controlled clinical trial. <i>Journal of pharmaceutical health care and sciences</i> . 2021 Dec;7(1):1-0.	Small sample size of episodic migraine
48. Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. <i>Canadian journal of neurological sciences</i> . 1992 Aug;19(3):340-5.	Small sample size of episodic migraine
49. Keyvan G, Abolfazl MB. Comparison of treatment effect of sodium valproate, propranolol and tricyclic antidepressants in migraine. <i>Pakistan journal of biological sciences: PJBS</i> . 2009 Aug 1;12(15):1098-101.	Small sample size
50. Hussein HS, Alsalihi NJ, Al Gawwam G. Flunarizine Vs Propranolol in the Prevention of Migrainous Headache Attacks. <i>Age (years)</i> . 2021;30(9):30-4.	Small sample size
51. Ghose K, Niven BE, Berry D. A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache. <i>The Journal of Headache and Pain</i> . 2002 Sep;3(2):79-85.	Small sample size
52. Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, Dodick DW. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. <i>Neurology</i> . 2020 Nov 3;95(18):e2487-99.	Comparing dosing regime of same drug
53. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Wright IK, Chou DE, Klatt J, Picard H, Lenz RA. One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. <i>Neurology</i> . 2020 Aug 4;95(5):e469-79.	Reporting the active treatment phase with dose blinding not the RCT part
54. Goadsby PJ, Reuter U, Lanteri-Minet M, da Silva Lima GP, Hours-Zesiger P, Fernandes C, Wen S, Tenenbaum N, Kataria A, Ferrari MD, Klatt J. Long-Term efficacy and safety of Erenumab: results from 64 weeks of the liberty study. <i>Neurology</i> . 2021 Jun 1;96(22):e2724-35.	Reporting the open label phase
55. Grahame R. Drug prophylaxis in migraine. <i>British Medical Journal</i> . 1960 Oct 10;2(5207):1203.	Small sample size of episodic migraine
56. Rompel, H. & Bauermeister PW. Aetiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study. <i>South African Medical Journal</i> . 1970 Jan 1;44(4):75-80.	Small sample size of episodic migraine
57. Havanka-Kanniainen H, Hokkanen E, Myllylä VV. Efficacy of nimodipine in comparison with pizotifen in the prophylaxis of migraine. <i>Cephalalgia</i> . 1987 Mar;7(1):7-13.	Small sample size of episodic migraine
58. Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME. The effect of beginning treatment with fremanezumab on	Some arms more than 100 participants per arm and some

headache and associated symptoms in the randomized phase 2 study of high frequency episodic migraine: Post-hoc analyses on the first 3 weeks of treatment. <i>Headache: The Journal of Head and Face Pain</i> . 2019 Mar;59(3):383-93.	less than 100
59. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. <i>Cephalalgia</i> . 1992 Apr;12(2):81-4.	Small sample size of episodic migraine
60. Hirata K, Takeshima T, Sakai F, Tatsuoka Y, Suzuki N, Igarashi H, Nakamura T, Ozeki A, Yamazaki H, Skljarevski V. A long-term open-label safety study of galcanezumab in Japanese patients with migraine. <i>Expert Opinion on Drug Safety</i> . 2021 Jun 3;20(6):721-33.	Reporting open label trial not RCT
61. Hollanda L, Monteiro L, Melo A. Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial. <i>Neurology International</i> . 2014 Dec 5;6(4):5133.	Assesses cutaneous allodynia rather than headache improvement
62. Hou M, Xie JF, Kong XP, Zhang Y, Shao YF, Wang C, Ren WT, Cui GF, Xin L, Hou YP. Acupoint injection of onabotulinumtoxin A for migraines. <i>Toxins</i> . 2015 Oct 30;7(11):4442-54.	Small sample size of episodic migraine
63. Mehvari J, Rafieian-Kopaei M. Prophylactic activity of cyproheptadine and Bellergal on migraine headache. <i>Iranian Journal of Medical Sciences</i> . 2005 Jun 1;30(2).	Small sample size of episodic migraine
64. Song JH, Zhang GB, Ding XD, Huang L, Hong Y, Chen HX. Efficacy of type a botulinum toxin injections and infrared polarized light on treating chronic migraine. <i>Eur Rev Med Pharmacol Sci</i> . 2015 Jan 1;19(11):1976-82.	Poor quality paper and small size.
65. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis: changes in pattern of attacks during a controlled clinical trial. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 1973 Aug 1;36(4):684-90.	Small sample size of episodic migraine
66. Jedynek J, Eross E, Gendolla A, Rettiganti M, Stauffer VL. Shift from high-frequency to low-frequency episodic migraine in patients treated with galcanezumab: results from two global randomized clinical trials. <i>The Journal of Headache and Pain</i> . 2021 Dec;22(1):1-0.	No report of adverse events
67. Grottemeyer KH, Schlake HP, Husstedt IW. Etilefrine Pivalate vs. Dihydroergotamin and Flunarizin in Prophylactic Treatment of Migraine in Patients with Low Blood Pressure—A Randomized Double-Blind-Study. <i>Cephalalgia</i> . 1989 Oct;9(10_suppl):433-4.	Small sample size of episodic migraine
68. Welch KM. 11: Naproxen Sodium in the Treatment of Migraine. <i>Cephalalgia</i> . 1986 Apr;6(4_suppl):85-92.	Small sample size of episodic migraine
69. Kuruppu DK, Tobin J, Dong Y, Aurora SK, Yunes-Medina L, Green AL. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments. <i>BMC neurology</i> . 2021 Dec;21(1):1-9.	No report of adverse events
70. Lai KL, Niddam DM, Fuh JL, Chen SP, Wang YF, Chen WT, Wu JC, Wang SJ. Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. <i>Acta Neurologica Scandinavica</i> . 2017 Apr;135(4):476-83.	Small sample size
71. Landy S, McGinnis J, Curlin D, Laizure SC. Selective serotonin reuptake inhibitors for migraine prophylaxis. <i>Headache: The Journal of Head and Face Pain</i> . 1999 Jan;39(1):28-32.	Small sample size of episodic migraine
72. Lepcha A, Amalanathan S, Augustine AM, Tyagi AK, Balraj A. Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. <i>European Archives of Oto-Rhino-Laryngology</i> . 2014 Nov;271(11):2931-6.	Vertigo migraine
73. Lipton RB, Cohen JM, Galic M, Seminerio MJ, Yeung PP, Aycardi E, Bigal ME, Bibeau K, Buse DC. Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study. <i>Headache: The Journal of Head and Face</i>	Content of this paper is out of scope

Pain. 2021 Apr;61(4):662-72.	
74. Loeb LM, Amorim RP, Mazzacoratti MD, Scorza FA, Peres MF. Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison. Arquivos de neuro-psiquiatria. 2018;76:663-7.	Small study only 18 patients in OnabotulinumtoxinA group.
75. Louis P, Spierings EL. Comparison of flunarizine (Sibelium®) and pizotifen (Sandomigran®) in migraine treatment: A double-blind study. Cephalalgia. 1982 Dec 1;2(4):197-203.	Small sample size of episodic migraine
76. Luo N, Di W, Zhang A, Wang Y, Ding M, Qi W, Zhu Y, Massing MW, Fang Y. A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Medicine. 2012 Jan 1;13(1):80-6.	Small sample size
77. Siniatchkin M, Andrasik F, Kropp P, Niederberger U, Strenge H, Averkina N, Lindner V, Stephani U, Gerber WD. Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study. Cephalalgia. 2007 Sep;27(9):1024-32.	Small sample size
78. Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. The Lancet Neurology. 2015 Nov 1;14(11):1081-90.	Number of participants 96 in treatment group 104 in placebo- doesn't meet criteria of 100 per arm
79. Simmonds MK, Rashedi S, Sobolev IA, Dick BD, Gray DP, Stewart BJ, Jamieson-Lega KI. The effect of single-dose propofol injection on pain and quality of life in chronic daily headache: a randomized, double-blind, controlled trial. Anesthesia & Analgesia. 2009 Dec 1;109(6):1972-80.	Small sample size, chronic daily headache
80. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, Botox CDH Study Group. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Headache: The Journal of Head and Face Pain. 2005 Apr;45(4):293-307.	CDH of which CM is a subset, but as not specific to CM
81. Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxin (BOTOX®) and topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: A pilot study. Headache: The Journal of Head and Face Pain. 2009 Nov;49(10):1466-78.	Small sample size
82. Mazdeh M, Mahmudian R, Vafaei SY, Taheri M, Ghafouri-Fard S. Effect of propranolol with and without rosuvastatin on migraine attacks: a triple blind randomized clinical trial. Future Neurology. 2020 May;15(2):FNL44.	Small sample size
83. Homam M, Farajpour A, Khadem S, Mostafavian Z. The experiential comparison of levetiracetam efficacy in migraine headache with sodium valproate. Caspian Journal of Neurological Sciences. 2016 Jun 10;2(2):42-9.	Small sample size
84. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, Rivera-Castano L, Garcia-Solorzano A, López-Blanca C, Membrilla-Maldonado M, Muñoz-Solis R. Subcutaneous histamine versus sodium valproate in migraine prophylaxis: A randomized, controlled, double-blind study. European journal of neurology. 2007 Oct;14(10):1079-84.	Small sample size of episodic migraine
85. Millán-Guerrero RO, Isais-Millán S, Barreto-Vizcaino S, Rivera-Castaño L, Rios-Madariaga C. Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study. European journal of neurology. 2009 Jan;16(1):88-94.	Small sample size of episodic migraine
86. Mogollón J, Serrano A, Padrón de Freitez A, Uzcátegui E, Baptista T. Olanzapine as an add-on treatment in migraine status: A randomized double-blind, placebo-controlled, pilot study. The European Journal of	Acute Migraine

Psychiatry. 2012 Dec;26(4):260-5.	
87. Hasan MK, Khan I, Salam T, Sharmin M. The Sociodemographic Characteristics of Migraine Patients in Bangladesh. <i>Int J Med Res Prof.</i> 2019;59-62.	Small sample size of episodic migraine
88. Choudhary MU, Nawaz J, Saddique MU, Zameer A. Comparison between topiramate and sodium valproate efficacy in the treatment of migraine. <i>Pak J Med Health Sci.</i> 2017 Jul 1;11(3):1005-7.	Small sample size of episodic migraine
89. Naderinabi B, Saberi A, Hashemi M, Haghighi M, Biazar G, Gharehdaghi FA, Sedighinejad A, Chavoshi T. Acupuncture and botulinum toxin A injection in the treatment of chronic migraine: a randomized controlled study. <i>Caspian Journal of Internal Medicine.</i> 2017;8(3):196.	Small sample size
90. Nappi G, Sandrini G, Savoini G, Cavallini A, De Rysky C, Micieli G. Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine. <i>Drugs.</i> 1987 Mar;33(2):103-9.	Small sample size of episodic migraine
91. Nichols R, Doty E, Sacco S, Ruff D, Pearlman E, Aurora SK. Analysis of initial nonresponders to galcanezumab in patients with episodic or chronic migraine: results from the EVOLVE-1, EVOLVE-2, and REGAIN randomized, double-blind, placebo-controlled studies. <i>Headache: The Journal of Head and Face Pain.</i> 2019 Feb;59(2):192-204.	Mixed population
92. Olsson JE, Behring HC, Forssman B, Hedman C, Hedman G, Johansson FA, Kinnman J, Pålhagen SE, Samuelsson M, Strandman E. Metoprolol and propranolol in migraine prophylaxis: a double-blind multicentre study. <i>Acta neurologica scandinavica.</i> 1984 Sep;70(3):160-8.	Small sample size of episodic migraine
93. Omranifard M, Abdali H, Ardakani MR, Talebianfar M. A comparison of outcome of medical and surgical treatment of migraine headache: In 1 year follow-up. <i>Advanced Biomedical Research.</i> 2016;5.	Small sample size
94. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. <i>Cephalalgia.</i> 2004 Jan;24(1):60-5.	Mixed of chronic tension type and chronic migraine headaches.
95. Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. <i>Headache: The Journal of Head and Face Pain.</i> 2005 Feb;45(2):144-52.	Small sample size
96. Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. <i>Cephalalgia.</i> 1984 Jun;4(2):91-6.	Small sample size
97. Kangasniemi PJ, Nyrke T, Lang AH, Petersen E. Femoxetine-a new 5-HT uptake inhibitor-and propranolol in the prophylactic treatment of migraine. <i>Acta neurologica scandinavica.</i> 1983 Oct;68(4):262-7.	Drug not available and small sample size
98. Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. <i>The Lancet Neurology.</i> 2020 Sep 1;19(9):727-37.	Some arms have less than 100 per arm and some more than 100
99. Pijpers JA, Kies DA, Louter MA, van Zwet EW, Ferrari MD, Terwindt GM. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. <i>Brain.</i> 2019 May 1;142(5):1203-14.	Small sample size
100. Pradalier A, Serratrice G, Collard M, Hirsch E, Feve J, Masson M, Masson C, Dry J, Koulikovsky G, Nguyen G, Schbath J. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. <i>Cephalalgia.</i> 1989 Dec;9(4):247-53.	Small sample size
101. Pradalier A, Lantéri-Minet M, Géraud G, Attain H, Lucas C, Delgado A. The PROMISE study: PROphylaxis of migraine with SEglor®(dihydroergotamine mesilate) in French primary care. <i>CNS drugs.</i>	No report of adverse events

2004 Dec;18(15):1149-63.	
102. Rahimdel A, Zeinali A, Yazdian-Anari P, Hajizadeh R, Arefnia E. Effectiveness of vitamin B2 versus sodium valproate in migraine prophylaxis: a randomized clinical trial. <i>Electronic Physician</i> . 2015 Oct;7(6):1344	Small sample size
103. Rapoport A, Mauskop A, Diener HC, Schwalen S, Pfeil J. Long-term migraine prevention with topiramate: open-label extension of pivotal trials. <i>Headache: The Journal of Head and Face Pain</i> . 2006 Jul;46(7):1151-60.	Mixed population of adults and adolescence, no results for only adult
104. Rasmussen MJ, Holt Larsen B, Borg L, Soelberg Sørensen P, Hansen PE. Tolfenamic acid versus propranolol in the prophylactic treatment of migraine. <i>Acta neurologica scandinavica</i> . 1994 Jun;89(6):446-50.	Small sample size
105. Kaushik R, Kaushik RM, Mahajan SK, Rajesh V. Biofeedback assisted diaphragmatic breathing and systematic relaxation versus propranolol in long term prophylaxis of migraine. <i>Complementary therapies in medicine</i> . 2005 Sep 1;13(3):165-74.	Small sample size
106. Lipton RB, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, Biondi DM, Ascher S, Olson WH, Hulihan J. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. <i>Cephalalgia</i> . 2011 Jan;31(1):18-30.	Participants were aged 12-70, so not exclusively adult population and data for adults is not reported separately
107. Ryan Sr RE. Comparative study of nadolol and propranolol in prophylactic treatment of migraine. <i>American Heart Journal</i> . 1984 Oct 1;108(4):1156-9.	Small sample size
108. Ryan RE, Diamond S, Ryan RE. Double blind study of clonidine and placebo for the prophylactic treatment of migraine. <i>Headache: The Journal of Head and Face Pain</i> . 1975 Oct;15(3):202-6.	Small sample size
109. Ildfonso RL, Martín SA, Francisco HS, Mandeville Peter B, del Rocío RL, Manuel SM, Humberto TP. Topiramate vs. Amitriptyline in prophylactic treatment of migraine: A controlled clinical trial. <i>Rev Mex Neurosci</i> . 2010;11(5):338-42.	Small sample size
110. Weber RB, Reinmuth OM. The treatment of migraine with propranolol. <i>Neurology</i> . 1972 Apr 1;22(4):366-9.	Small sample size
111. Ruff DD, Ford JH, Tockhorn-Heidenreich A, Stauffer VL, Govindan S, Aurora SK, Terwindt GM, Goadsby PJ. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. <i>European journal of neurology</i> . 2020 Apr;27(4):609-18.	No report of adverse events
112. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine—a randomized, double-blind, placebo-controlled study. <i>Cephalalgia</i> . 2004 Oct;24(10):838-43.	Small sample size
113. Ghobadi SH, Jivad N. The prophylactic activity of propranol and nimodipineon migraine headache. <i>World J Med Sci</i> . 2013;8(2):144-6.	Small sample size
114. Sadeghian H, Motiei-Langroudi R. Comparison of Levetiracetam and sodium Valproate in migraine prophylaxis: A randomized placebo-controlled study. <i>Annals of Indian Academy of Neurology</i> . 2015 Jan;18(1):45.	Small sample size
115. Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y, Cheng S, Hiram T, Mikol DD. A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. <i>Headache: The Journal of Head and Face Pain</i> . 2019 Nov;59(10):1731-42.	Small sample size
116. Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y, Peng C, Xue F, Mikol DD. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine. <i>Headache: The Journal of Head and Face Pain</i> . 2021 Apr;61(4):653-61.	Small sample size

117. Santiago MD, Carvalho DD, Gabbai AA, Pinto MM, Moutran AR, Villa TR. Amitriptyline and aerobic exercise or amitriptyline alone in the treatment of chronic migraine: a randomized comparative study. <i>Arquivos de neuro-psiquiatria</i> . 2014;72:851-5.	Small sample size
118. Saper JR, Lake III AE, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. <i>Headache: The Journal of Head and Face Pain</i> . 2002 Jun;42(6):470-82.	Small sample size
119. Schellenberg R, Lichtenthal A, Wöhling H, Graf C, Brixius K. Nebivolol and Metoprolol for Treating Migraine: An Advance on β -Blocker Treatment?. <i>Headache: The Journal of Head and Face Pain</i> . 2008 Jan;48(1):118-25.	Small sample size
120. Seng EK, Holroyd KA. Behavioral migraine management modifies behavioral and cognitive coping in people with migraine. <i>Headache: The Journal of Head and Face Pain</i> . 2014 Oct;54(9):1470-83.	Not drug trial – small sample size
121. Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. <i>Clinical neurology and neurosurgery</i> . 2004 Dec 1;107(1):44-8.	Small sample size
122. Sonbolestan SA, Heshmat K, Javanmard SH, Saadatnia M. Efficacy of enalapril in migraine prophylaxis: a randomized, double-blind, placebo-controlled trial. <i>International Journal of Preventive Medicine</i> . 2013 Jan;4(1):72.	Small sample size
123. Rafie S, Karimian F, Ghomifar A, Karimian A. Effect of Pramipexole on Headache Relief in Patients with Concomitant Migraine and Restless Legs Syndrome; A Randomized, Controlled, Clinical Trial. <i>Jundishapur Journal of Natural Pharmaceutical Products</i> . 2019 Aug 31;14(3).	Small sample size
124. Shehata HS, Esmail EH, Abdelalim A, El-Jaafary S, Elmazny A, Sabbah A, Shalaby NM. Repetitive transcranial magnetic stimulation versus botulinum toxin injection in chronic migraine prophylaxis: a pilot randomized trial. <i>Journal of pain research</i> . 2016;9:771.	Small sample size
125. Silberstein SD, Collins SD, Long-term Safety of Depakote in Headache Prophylaxis Study Group. Safety of divalproex sodium in migraine prophylaxis: An open-label, long-term study. <i>Headache: The Journal of Head and Face Pain</i> . 1999 Oct;39(9):633-43.	Not a RCT
126. Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. <i>Archives of Neurology</i> . 2004 Apr 1;61(4):490-5.	Mixed population of adults and adolescence
127. Silberstein SD, Dodick DW, Lindblad AS, Holroyd K, Harrington M, Mathew NT, Hirtz D. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. <i>Neurology</i> . 2012 Mar 27;78(13):976-84.	Small sample size
128. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. <i>Cephalalgia</i> . 2003 Oct;23(8):820-4.	Small sample size
129. Skljarevski V, Oakes TM, Zhang QI, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. <i>JAMA neurology</i> . 2018 Feb 1;75(2):187-93.	Small sample size
130. Sørensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. <i>Cephalalgia</i> . 1986 Mar;6(1):7-14.	Small sample size
131. Silberstein SD, Loder E, Forde G, Papadopoulos G, Fairclough D, Greenberg S. The impact of migraine on daily activities: effect of topiramate compared with placebo. <i>Current medical research and</i>	No report of adverse events

opinion. 2006 Jun 1;22(6):1021-9.	
132. Silberstein S, Goode-Sellers S, Twomey C, Saiers J, Ascher J. Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia. 2013 Jan;33(2):101-11.	Small sample size
133. Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, Hagen K. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014 Jun;34(7):523-32.	Small sample size
134. Sujan MU, Rao MR, Kisan R, Abhishekh HA, Nalini A, Raju TR, Sathyaprabha TN. Influence of hydrotherapy on clinical and cardiac autonomic function in migraine patients. Journal of neurosciences in rural practice. 2016 Jan;7(01):109-13.	Not drug trial
135. Zain S, Khan M, Alam R, Zafar I, Ahmed S. Comparison of efficacy and safety of topiramate with gabapentin in migraine prophylaxis: randomized open label control trial. J Pak Med Assoc. 2013 Jan 1;63(1):3-7.	Small sample size
136. Tatsuoaka Y, Takeshima T, Ozeki A, Matsumura T. Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study. Neurology and therapy. 2021 Jun;10(1):265-78.	No report of adverse events
137. Oakes TM, Skljarevski V, Zhang Q, Kielbasa W, Hodsdon ME, Detke HC, Camporeale A, Saper JR. Safety of galcanezumab in patients with episodic migraine: a randomized placebo-controlled dose-ranging phase 2b study. Cephalalgia. 2018 May;38(6):1015-25.	Small sample size
138. Titus F, Dávalos A, Alom J, Codina A. 5-hydroxytryptophan versus methysergide in the prophylaxis of migraine. European neurology. 1986;25(5):327-9.	Small sample size
139. Steiner TJ, Ahmed F, Findley LJ, MacGregor EA, Wilkinson M. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia. 1998 Jun;18(5):283-6.	Small sample size
140. Vahedi K, Taupin P, Djombly RF, El-Amrani M, Lutz G, Filipetti V, Landais P, Massiou H, Bousser MG. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. Journal of neurology. 2002 Feb;249(2):206-11.	Small sample size
141. Todorov V, Bogdanova D, Tonchev P, Milanov I. Repetitive transcranial magnetic stimulation over two target areas, sham stimulation and topiramate in the treatment of chronic migraine. Comptes rendus de l'Académie bulgare des Sciences. 2020 Jan 1;73(9).	Small sample size
142. Villani V, Prosperini L, Palombini F, Orzi F, Sette G. Single-blind, randomized, pilot study combining shiatsu and amitriptyline in refractory primary headaches. Neurological Sciences. 2017 Jun;38(6):999-1007.	Small sample size
143. Wammes-van der EA, Smidt MH, Tijssen CC, Van 't Hoff AR, Lenderink, PharmD AW, Egberts, PharmD AC. Effect of low-intensity acenocoumarol on frequency and severity of migraine attacks. Headache: The Journal of Head and Face Pain. 2005 Feb;45(2):137-43.	Small sample size
144. Xu JH, Mi HY. A randomized controlled trial of acupressure as an adjunctive therapy to sodium valproate on the prevention of chronic migraine with aura. Medicine. 2017 Jul;96(27).	Not a drug trial
145. Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. The journal of headache and pain. 2008 Feb;9(1):37-41.	Small sample size
146. Zidan A, Hussaini S, Gibson S, Brooks G, Mejico L.	Trial of OnabotulinumtoxinA

Onabotulinumtoxin Type A reconstitution with preserved versus preservative-free saline in chronic migraine (B-RECON). A randomised, double-blind trial. <i>International Journal of Clinical Practice</i> . 2020 Sep;74(9):e13522.	preservative on injection site pain
147. Silberstein SD, Hulihan J, Karim MR, Wu SC, Jordan D, Karvois D, Kamin M. Efficacy and tolerability of topiramate 200mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. <i>Clinical therapeutics</i> . 2006 Jul 1;28(7):1002-11.	Episodic, small
148. Askari G, Nasiri M, Mozaffari-Khosravi H, Rezaie M, Bagheri-Bidakhavid M, Sadeghi O. The effects of folic acid and pyridoxine supplementation on characteristics of migraine attacks in migraine patients with aura: A double-blind, randomized placebo-controlled, clinical trial. <i>Nutrition</i> . 2017 Jun 1;38:74-9.	Acute migraine
149. Hajhashemi P, Askari G, Khorvash F, Reza Maracy M, Nourian M. The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial. <i>Cephalalgia</i> . 2019 Apr;39(5):648-54.	Small sample size of episodic migraine
150. Bredfeldt RC, Sutherland JE, Kruse JE. Efficacy of transdermal clonidine for headache prophylaxis and reduction of narcotic use in migraine patients. <i>J Fam Pract</i> . 1989;29(2):153-6.	Small episodic migraine
151. Centonze V, Macinagrossa G, Attolini E, Magrone D, Trizio T, Tesauro P, Campanozzi F, Altomare E, Albano O. Terapia preventiva dell'emicrania: flunarizina versus verapamil [Preventive therapy of migraine: flunarizine versus verapamil]. <i>Clin Ter</i> . 1985 Dec 15;115(5):333-9. Italian. PMID: 3830537.	Small episodic migraine
152. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. <i>Headache: The Journal of Head and Face Pain</i> . 2004 Oct;44(9):885-90.	Small sample size of episodic migraine
153. Chitsaz A, Ghorbani A, Hoseinzadeh H, Nazari F, Norouzi R, Tajic S. Comparison of botulinum toxin type-A and divalproex sodium for prevention of chronic and episodic migraine. <i>Neurology Asia</i> . 2012 Jun 1;17(2).	Small sample size
154. Matin H, Taghian F, Chitsaz A. Artificial intelligence analysis to explore synchronize exercise, cobalamin, and magnesium as new actors to therapeutic of migraine symptoms: a randomized, placebo-controlled trial. <i>Neurological Sciences</i> . 2022 Feb 3:1-2.	Small sample size of episodic migraine
155. Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. <i>The Lancet</i> . 2021 Jan 2;397(10268):51-60.	Small sample size
156. Diamond S, Kudrow L, Stevens J, Shapiro DB. Long-term study of propranolol in the treatment of migraine. <i>Headache: The Journal of Head and Face Pain</i> . 1982 Nov;22(6):268-71.	No outcome of interests
157. Mottaghi T, Askari G, Khorvash F, Maracy MR. Effect of Vitamin D supplementation on symptoms and C-reactive protein in migraine patients. <i>Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences</i> . 2015 May;20(5):477.	Participants aged 10-61 so not all adult population
158. Nattagh-EshTVani E, Dahri M, Hashemilar M, Tarighat-Esfanjani A. The effect of coenzyme Q10 supplementation on serum levels of lactate, pyruvate, matrix metalloproteinase 9 and nitric oxide in women with migraine. A double blind, placebo, controlled randomized clinical trial. <i>European Journal of Integrative Medicine</i> . 2018 Aug 1;21:70-6.	Small sample size of episodic migraine
159. Shoeibi A, Olfati N, Soltani Sabi M, Salehi M, Mali S, Akbari Oryani M. Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial. <i>Acta Neurologica</i>	Small sample size of episodic migraine

Belgica. 2017 Mar;117(1):103-9.	
160. Tarighat Esfanjani A, Mahdavi R, Ebrahimi Mameghani M, Talebi M, Nikniaz Z, Safaiyan A. The effects of magnesium, l-carnitine, and concurrent magnesium–l-carnitine supplementation in migraine prophylaxis. <i>Biological trace element research</i> . 2012 Dec;150(1):42-8.	Small sample size of episodic migraine
161. Hsieh LL, Liou HH, Lee LH, Chen TH, Yen AM. Effect of acupressure and trigger points in treating headache: a randomized controlled trial. <i>The American Journal of Chinese Medicine</i> . 2010;38(01):1-4.	Small sample size of episodic migraine
162. Langohr HD, Gerber WD, Koletzki E, Mayer K, Schroth G. Clomipramine and Metoprolol in Migraine Prophylaxis—A Double-blind Crossover Study. <i>Headache: The Journal of Head and Face Pain</i> . 1985 Mar;25(2):107-12.	Small episodic migraine
163. Sândor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. <i>Neurology</i> . 2005 Feb 22;64(4):713-5.	Episodic and less than 100 per arm
164. Mathew NT. Prophylaxis of migraine and mixed headache. A randomized controlled study. <i>Headache: The Journal of Head and Face Pain</i> . 1981 May;21(3):105-9.	Small sample size
165. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis A randomized controlled trial. <i>Neurology</i> . 1998 Feb 1;50(2):466-70.	Episodic and less than 100 per arm
166. Cao K, Yu L, Gao Y, Fan Y, Zhao J, Zhang X, Xie W, Yang W, Dong M, Li T, Qiao X. Efficacy of zhengtian pill for migraine prophylaxis: a randomized, multicenter, double-blind, placebo-controlled, parallel-group study. <i>European Journal of Integrative Medicine</i> . 2014 Jun 1;6(3):259-67.	Herbal remedy not prescribed on NHS
167. Nelson CF, Bronfort G, Evans R, Boline P, Goldsmith C, Anderson AV. The efficacy of spinal manipulation, amitriptyline and the combination of both therapies for the prophylaxis of migraine headache. <i>Journal of manipulative and physiological therapeutics</i> . 1998 Oct 1;21(8):511-9.	Small episodic migraine
168. Diener HC, Kronfeld K, Boewing G, Lungenhausen M, Maier C, Molsberger A, Tegenthoff M, Trampisch HJ, Zenz M, Meinert R, GERAC Migraine Study Group. Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. <i>The Lancet Neurology</i> . 2006 Apr 1;5(4):310-6.	Episodic, control treatment not standardised
169. Shukla R, Garg RK, Nag D, Ahuja RC. Nifedipine in migraine and tension headache: a randomised double blind crossover study. <i>The Journal of the Association of Physicians of India</i> . 1995 Nov 1;43(11):770-2.	Small episodic migraine
170. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC, BoNTA-039 Study Group. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. In <i>Mayo Clinic Proceedings</i> 2005 Sep 1 (Vol. 80, No. 9, pp. 1126-1137). Elsevier.	Paper has included mixed patients (77% chronic migraine, 18% chronic tension type headache, 3% new daily persistent headache and 1% other headaches). Not all patients were chronic migraineurs.
171. Ford JH, Stauffer VL, McAllister P, Akkala S, Sexson M, Ayer DW, Wang S. Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study. <i>Quality of Life Research</i> . 2021 Feb;30(2):455-64.	Episodic, small, no placebo control
172. Anthony M. Interesting uses of beta blockers. 1. Beta blockers in migraine prevention. <i>Australian family physician</i> . 1981 Apr;10(4):258-62.	Not an RCT

173. Arthur GP, Hornabrook RW. The treatment of migraine with BC 105 (pizotifen): a double blind trial. The New Zealand Medical Journal. 1971 Jan 1;73(464):5-9.	Small episodic migraine
174. Ashkenazi A, Silberstein S. Botulinum toxin type A for the treatment of headache: why we say yes. Archives of neurology. 2008 Jan 1;65(1):146-9.	Not an RCT
175. Bademosi O, Osuntokun BO. Pizotifen in the management of migraine. The Practitioner. 1978 Feb 1;220(1316):325-7.	Small episodic migraine
176. Behan PO, Reid M. Propranolol in the treatment of migraine. The Practitioner. 1980 Feb;224(1340):201-3.	Small episodic migraine
177. Chen SP, Fuh JL, Wang SJ. OnabotulinumtoxinA: preventive treatment for chronic migraine. Current pain and headache reports. 2011 Feb;15(1):4-7.	Not an RCT
178. Diamond S, Freitag FG. A double-blind trial of flunarizine in migraine prophylaxis. Headache Quarterly-Current Treatment and Research. 1993 Jan 1;4(2):169-72.	Small episodic migraine
179. Feuerstein T, Quebe-Fehling E. A double-blind, placebo-controlled, parallel-group, multicenter study of the safety and efficacy of gabapentin (CI-945) as a prophylactic interval therapy in patients with common migraine (Protocols 879-201,-205,-206,-207,-209). Research Report No. RR 4301-00066. Freiburg: Goedecke AG Research and Development. Available at: http://dida.library.ucsf.edu/pdf/brr13j10 1990. Accessed May 26; 2015.	Small episodic migraine
180. Hübbe P. Controlled clinical trials of drugs for use in the prophylaxis of migraine. Danish Medical Bulletin. 1975 Mar 1;22(3):92-6.	Not an RCT
181. Lance JW, Curran DA, Anthony M. Investigations into the mechanism and treatment of chronic headache. Medical journal of Australia. 1965 Nov;2(22):909-14.	Not an RCT
182. Magnus-Miller L, Bernstein P, Caswell K. Double-blind, randomized, placebo-controlled, multicenter trial to determine the efficacy and safety of Neurontin®(gabapentin) in migraine prophylaxis administered in doses divided three times a day (TID)(protocol 945-220). Research Report No. RR 995-00074. Morris Plains, NJ: Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company Medical and Scientific Affairs Department; August 24, 1999. Available at: http://dida.library.ucsf.edu/pdf/arr13j10 . 1999 Aug 24.	Small episodic migraine
183. Magnus-Miller L, Bernstein P, Caswell K. Double-blind, randomized, placebo-controlled, multicenter trial to determine the efficacy and safety of Neurontin®(gabapentin) in migraine prophylaxis administered in doses divided three times a day (TID)(protocol 945-220). Research Report No. RR 995-00074. Morris Plains, NJ: Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company Medical and Scientific Affairs Department; August 24, 1999. Available at: http://dida.library.ucsf.edu/pdf/arr13j10 . 1999 Aug 24.	Small episodic migraine
184. Linde K, Rossnagel K. WITHDRAWN: Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2017;2(2):CD003225. Published 2017 Feb 17. doi:10.1002/14651858.CD003225.pub3	Not an RCT
185. Nair KG. A pilot study of the value of propranolol in migraine. Journal of postgraduate medicine. 1975 Jul;21(3):111-3.	Small episodic migraine
186. Pita E, Higuera A, Bolanos J, Perez N, Mundo A. Propranolol and migraine. A clinical trial. Archivos de Farmacologia y Toxicologia. 1977 Dec 1;3(3):273-8.	Small episodic migraine
187. Verstraete M, Verhaeghe R. 20 Drugs acting on the cerebral and peripheral. Side Effects of Drugs Annual. 1977;10:172.	Small episodic migraine
188. Rothrock JF. Topiramate for chronic migraine.	Not an RCT

189. Ryan Sr RE, Ryan Jr RE, Sudilovsky A. Nadolol and placebo comparison study in the prophylactic treatment of migraine. <i>Panminerva medica</i> . 1982;24(2):89-94.	Small episodic migraine
190. Saper JR, Good DC, Michalek J, Kaplan RJ, Xiao Y, Nadler S. Efficacy and tolerability of tizanidine as adjunctive therapy in the prophylaxis of chronic daily headache. <i>Round Table Series-Royal Society of Medicine</i> . 2002 Jan 1(75):13-22.	Small sample size
191. Yuan C, Wang JX, Yu JP, Yan F, Su SH. A double-blind trial of 5 calcium channel blockers in prophylaxis of migraine. <i>CHINESE JOURNAL OF CLINICAL PHARMACOLOGY</i> . 1998;14:14-7.	Small episodic migraine
192. Mattimoe D, Newton W. High-dose riboflavin for migraine prophylaxis. <i>The Journal of Family Practice</i> . 1998 Jul 1;47(1):11-.	Small sample size
193. Gonçalves DA, Camparis CC, Speciali JG, et al. Treatment of comorbid migraine and temporo-mandibular disorders: A factorial, double-blind, ran-domized, placebo-controlled study. <i>J Orofac Pain</i> . 2013;27:325-335	Episodic, small
194. Schoenen J, Jacqy J, Lenaerts M. High-dose riboflavin is effective in migraine prophylaxis: Results from a double blind, randomized, placebo controlled trial. In <i>Neurology</i> 1997 Mar 1 (Vol. 48, No. 3, pp. 8005-8005). 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106: LIPPINCOTT-RAVEN PUBL.	Small episodic migraine
195. Hübbe P. The prophylactic treatment of migraine with an antiserotonin pizotifen (BC 105). <i>Acta Neurologica Scandinavica</i> . 1973 Mar;49(1):108-14.	Episodic, small
196. Schoenen J, Jacqy J, Lenaerts ME, Loder E. High-dose riboflavin reduced the frequency of migraine headaches. <i>Evidence-Based Medicine</i> . 1998 Sep;3(5):151.	Small episodic migraine
197. Rezaeiashtiani A, Jadidi A, Khanmohammadi-Hezaveh A, Aghaeipour SM, Pourandish Y, Malekhosseini S, Ghassami K, Mohammadbeigi A. Is the treatment of constipation can relieve the migraine symptoms? A randomized clinical trial study. <i>Journal of Pediatric Neurosciences</i> . 2019 Oct;14(4):186.	Episodic, small
198. Shimell CJ, Fritz VU, Levien SL. A comparative trial of flunarizine and propranolol in the prevention of migraine. <i>South African Medical Journal</i> , 1990 Jan 1;77(2):75-7.	Episodic, small
199. Wang LP, Zhang XZ, Guo J, Liu HL, Zhang Y, Liu CZ, Yi JH, Wang LP, Zhao JP, Li SS. Efficacy of acupuncture for migraine prophylaxis: a single-blinded, double-dummy, randomized controlled trial. <i>PAIN®</i> . 2011 Aug 1;152(8):1864-71.	Episodic, small
200. Yang CP, Chang MH, Li TC, Hsieh CL, Hwang KL, Chang HH. Predicting prognostic factors in a randomized controlled trial of acupuncture versus topiramate treatment in patients with chronic migraine. <i>The Clinical Journal of Pain</i> . 2013 Nov 1;29(11):982-7.	Chronic, small
201. Manzoni, GC, et al., Multicentric, double-blind, randomized study on the efficacy and tolerance of dothiepin and amitriptyline for the prophylaxis of chronic migraine. <i>Giornale di neuropsicofarmacologia</i> . 1990; 12(5):179-184	Small sample size
202. Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. <i>New England Journal of Medicine</i> . 2019 Jul 11;381(2):142-9.	Acute migraine
203. Diener HC, Tfelt-Hansen P, Dahlöf C, et al. Topiramate in migraine prophylaxis. <i>J Neurol</i> 251, 943– 950 (2004). https://doi.org/10.1007/s00415-004-0464-6	Mixed population of adult and adolescents
204. Ailani J, Andrews JS, Tockhorn-Heidenreich A, Wenzel R, Rettiganti M. Effect of Galcanezumab on Total Pain Burden in Patients Who Had	No safety data for adverse events review and small

Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis. <i>Advances in Therapy</i> . 2022 Oct;39(10):4544-55.	sample for effectiveness review
205. Igarashi H, Shibata M, Ozeki A, Matsumura T. Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial. <i>Neurology and Therapy</i> . 2022 Oct 20:1-5.	No safety data for adverse events review
206. Chowdhury D, Chaudhuri JR, Ghosh P, Kulkarni R, Singh S, Thakur S, Thorat AV. Efficacy and tolerability of erenumab for prevention of episodic migraine in India. <i>Annals of Indian Academy of Neurology</i> . 2022 May;25(3):433.	Small sample
207. Igarashi H, Shibata M, Ozeki A, Day KA, Matsumura T. Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine. <i>Journal of Pain Research</i> . 2021;14:3555.	No safety data for adverse events review
208. Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y, Peng C, Xue F, Mikol DD. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine. <i>Headache: The Journal of Head and Face Pain</i> . 2021 Apr;61(4):653-61.	Small sample
209. Okonkwo R, Tockhorn-Heidenreich A, Stroud C, Paget MA, Matharu MS, Tassorelli C. Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study. <i>The journal of headache and pain</i> . 2021 Dec;22(1):1-1.	No safety data for adverse events review
210. Okonkwo R, Tockhorn-Heidenreich A, Stroud C, Paget MA, Matharu MS, Tassorelli C. Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study. <i>The journal of headache and pain</i> . 2021 Dec;22(1):1-1.	No safety data for adverse events review
211. Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, Lines C, Edvinsson L, Goadsby PJ, Michelson D. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. <i>Neurology</i> . 2014 Sep 9;83(11):958-66.	Discontinued due to liver toxicity